Hansford Jordan R
Children's Cancer Centre, Royal Children's Hospital, Melbourne, Victoria, Australia.
Division of Cancer, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
J Paediatr Child Health. 2019 Jan;55(1):10-12. doi: 10.1111/jpc.14325. Epub 2018 Nov 30.
Modern paediatric oncology practice has rapidly evolved from a fatal condition at diagnosis in the 1940s to modern survival rates of over 80%. With the advent of the 'omics' era and modern diagnostics platforms, we can now determine many of the molecular driving mechanisms of malignancy. Current molecular diagnostics trials PRISM and AIM/MNP, open in Australia, allow accurate diagnosis and determination of the molecular drivers of many cancers leading to new targeted opportunities for treatment. Unfortunately, clinical trial support, development and drug access for children has lagged behind. This is leaving clinicians and their institutions with increasingly difficult medical and ethical decisions, further complicating an already demanding profession.
现代儿科肿瘤学实践已从20世纪40年代诊断时的致命疾病迅速发展到如今超过80%的现代生存率。随着“组学”时代和现代诊断平台的出现，我们现在能够确定许多恶性肿瘤的分子驱动机制。目前在澳大利亚开展的分子诊断试验PRISM和AIM/MNP，可实现对多种癌症的准确诊断并确定其分子驱动因素，从而带来新的靶向治疗机会。不幸的是，儿童临床试验的支持、开展及药物可及性一直滞后。这使得临床医生及其所在机构面临越来越艰难的医疗和伦理决策，让本就要求严苛的职业更加复杂。
